CROSSJECT (FRA:74C) Research & Development: €0.00 Mil (TTM As of Dec. 2025)


FRA:74C CROSSJECT FRA:74C
42 GF Score
Price €1.75
GF Value €1.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CROSSJECT Research & Development?

CROSSJECT FRA:74C -0.91% 42 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:74C with a GF Score™ of 42/100 and a GF Value™ of €1.12 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CROSSJECT's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

CROSSJECT  (FRA:74C) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CROSSJECT Research & Development Related Terms

CROSSJECT Research & Development Historical Data

* Premium members only.

The historical data trend for CROSSJECT's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CROSSJECT Research & Development Chart

CROSSJECT Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CROSSJECT Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:74C
42GF Score
CROSSJECT FRA:74C
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CROSSJECT Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
CROSSJECT (FRA:74C) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on CROSSJECT and its competitors.
Is CROSSJECT's Research & Development too high?
CROSSJECT's current Research & Development is €0.00 Mil. Overall, CROSSJECT has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CROSSJECT's Research & Development compare to ISRG and BDX?
CROSSJECT's Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CROSSJECT and its competitors. CROSSJECT's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CROSSJECT stock overvalued right now?
Based on GuruFocus' analysis, CROSSJECT (FRA:74C) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.12, compared to a current price of €1.75 — trading 55.9% above its estimated fair value. The current Research & Development is €0.00 Mil. CROSSJECT's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CROSSJECT (FRA:74C), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CROSSJECT (FRA:74C) Overvalued in 2026?

Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued. The current stock price of €1.75 is trading 55.9% above its estimated GF Value™ of €1.12. GuruFocus considers CROSSJECT to be Significantly Overvalued.

Key valuation signals for FRA:74C:

  • Research & Development: €0.00 Mil
  • GF Value™: €1.12 vs. price of €1.75 (55.9% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the FRA:74C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CROSSJECT Business Description

Other Exchanges ALCJ:France74C:Germany
Address 60L avenue du 14 Juillet, Chenôve, FRA, 21300
CROSSJECT manufactures and markets needle-free drug self-injection system.
42GF Score

Get the complete analysis for FRA:74C

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.75
Price
€1.12
GF Value